{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-008904","form_type":"8-K","ticker":"IDXX","cik":"0000874716","company_name":"IDEXX LABORATORIES INC /DE","filed_at":"2026-02-02T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.874057+00:00","generated_at":"2026-05-16T05:50:50.281701+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"IDEXX Q4 revenue $1.09B (+14% YoY), EPS $3.08 (+18%); guides FY26 rev $4.63B-$4.72B","bullets":["Q4 revenue $1,091M (+14% as reported, +12% organic); EPS $3.08 (+18% as reported, +17% comparable).","Full year 2025 revenue $4,304M (+10%); EPS $13.08 (+23% reported, +14% comparable).","CAG Diagnostics recurring revenue grew 12% reported; record >1,900 IDEXX inVue Dx placements in Q4.","FY26 guidance: rev $4,632M-$4,720M (7.6%-9.6% reported growth); EPS $14.29-$14.80 (9%-13% growth).","Operating margin expanded 150 bps reported in Q4 to 28.9%; gross margin 60.3%, up 50 bps."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-008904","json":"https://secwatch.observer/filing/0001104659-26-008904.json","markdown":"https://secwatch.observer/filing/0001104659-26-008904.md","text":"https://secwatch.observer/filing/0001104659-26-008904.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/874716/000110465926008904/0001104659-26-008904-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/874716/000110465926008904/tm264623d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-16T05:50:50.281701+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}